Sabada Dube

BioPharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Burden and Risk Factors for Staphylococcus aureus-Related Sepsis among US Dialysis Patients: A Retrospective Claims-Based Cohort Study.

Burden and Risk Factors for Staphylococcus aureus-Related Sepsis among US Dialysis Patients: A Retrospective Claims-Based Cohort Study.

Journal: Kidney360

Published: April 30, 2026

Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.

Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.

Journal: Infectious diseases and therapy

Published: January 15, 2026

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.

Journal: Infectious diseases and therapy

Published: November 04, 2024

Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.

Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.

Journal: The Journal of infection

Published: October 29, 2024

Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.

Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.

Journal: Advances in therapy

Published: August 20, 2024

Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747].

Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747].

Journal: The Lancet regional health. Europe

Published: August 19, 2024

COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review.

COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review.

Journal: The oncologist

Published: June 18, 2024

Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals.

Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals.

Journal: PLoS computational biology

Published: May 03, 2024

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab.

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: April 17, 2024

Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups.

Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups.

Journal: Infectious diseases and therapy

Published: February 06, 2024

Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study.

Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study.

Journal: The Lancet regional health. Europe

Published: July 10, 2023

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.

Journal: The journal of allergy and clinical immunology. In practice

Published: April 20, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026